I had someone PM me trying to downplay leronlimab'

Quote:

---

If you look at the Akero data the 70 mg dose shows worse results than either of the lower dose? Why would that be? Highly elevated levels of FGF21 that are naturally seen in NASH reduce the level of it's receptor. Over longer periods of time than the 14 weeks of the trial will the lower doses show a reduction in the receptor? FGF21 reduces fibrosis through lowering TGFb/NF-Kb activity.

Pliant's drug blocks aVb1 which also works by lowering TGFb/NF-Kb. The only results are from a phase 1 trial that didn't address efficacy.

I wonder what other drug reduces TGFb/NF-Kb and has other ways to lower inflammation. Could it be leronlimab?

---